Document Detail

In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma.
MedLine Citation:
PMID:  12028023     Owner:  NLM     Status:  MEDLINE    
Evaluating the potential benefit of the new anthracycline, idarubicin (Ida), in lymphoma, 58 tumour samples from patients suffering from low-grade non-Hodgkin's lymphoma (L-NHL), were analysed in vitro for their sensitivity to 0.5 microg/ml Ida. This was compared with the sensitivity to other anthracyclines (0.5 microg/ml), using the fluorometric microculture cytotoxicity assay. A total of 132 samples from patients with acute leukaemia and a cell-line panel representing different resistance mechanisms was included for comparison. The median cell survival of L-NHL cells did not differ after exposing the cells to Ida or daunorubicin (Dnr), whereas epirubicin, doxorubicin (Dox) and mitoxantrone (Mitox) were significantly less cytotoxic than Ida (P < 0.001). The median cell survival in L-NHL cells did not differ from that of acute leukaemia cells after exposure to 0.5 microg/ml Ida, Dnr, Dox and Mitox. Cells from previously treated patients with L-NHL had a higher median survival than cells from untreated patients after exposure to all drugs, except for Ida. In samples from previously untreated patients, Spearman rank correlations were high (Rho = 0.81-0.90) between cell survival after exposure to Ida and the other anthracyclines. The same pattern was observed in the cell-line panel (Rho = 0.78-0.91) (P < 0.05). In contrast, low correlations (Rho = 0.24-0.42) were observed among samples from previously treated patients. Our results indicate a potential benefit of Ida in previously drug-treated patients with L-NHL.
Anna Aleskog; Elin Jonsson; Rolf Larsson; Peter Nygren; Jörgen Kristensen; Christer Sundström; Martin Höglund
Related Documents :
1358433 - Structural requirements of simple organic cations for recognition by multidrug-resistan...
7740083 - Inhibition of the atpase activity of p-glycoprotein by porphyrin photosensitization of ...
21186083 - Viability and proliferation of pluripotential cells delivered to tendon repair sites us...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  117     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-05-24     Completed Date:  2002-07-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  563-8     Citation Subset:  IM    
Department of Medical Sciences, University Hospital, S-751 85 Uppsala, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibiotics, Antineoplastic / pharmacology*
Cell Survival / drug effects
Idarubicin / pharmacology*
Leukemia / pathology
Lymphoma, Non-Hodgkin / pathology*
Middle Aged
Tumor Cells, Cultured
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 58957-92-9/Idarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Trisomy 3 in two paediatric post-transplant lymphomas.
Next Document:  The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture ...